The NC3Rs and the Cell and Gene Therapy Catapult are hosting a one day workshop to explore preclinical testing of cell-based therapies for cancer.
The workshop will focus on:
- The current best practice in developing cell-based therapies.
- The benefits and limitations of using animal and non-animal models.
- How translation can be enabled by the application of in vitro and computational methods.
- Funding opportunities in preclinical modelling of cell-based therapies.
The workshop will be chaired by Michaela Sharpe, Head of Clinical Development at the Cell and Gene Therapy Catapult. The day will incorporate networking sessions to facilitate conversations and spark collaborations.
Confirmed speakers include:
- Mark Aspinall-O'Dea, Retrogenix
- Graham Ball, Nottingham-Trent University/CompanDx
- Katie Bates, NC3Rs
- Alastair Hotblack, University College London
- Adam Hurlstone, University of Manchester
- Nick Medcalf, Innovate UK
- David Pan, Medical Research Council
- Peter Simpson, Medicines Discovery Catapult
- Lynsey Whilding, King's College London
Posters and exhibitors
Delegates will have the opportunity to present a poster of their work, and there are limited exhibitor opportunities available. Delegates are encouraged to submit abstracts on a topic relevant to the theme of the meeting and highlighting the potential 3Rs benefits.
To present a poster, please complete the abstract submission form and submit by Friday 09 November.
To secure an exhibitor slot, please complete the abstract submission form and submit by Friday 09 November.
We will let you know if you have been successful by Monday 12 November.
Attendance is free, but registration is essential. The closing date for registration is Friday 16 November.
You will need an NC3Rs website account to register. Please use your institutional email address when registering.